Thermo Fisher Scientific reported first-quarter 2026 results that exceeded market expectations on key financial metrics, but investor reaction was negative, with shares declining in premarket trading.
- The company posted adjusted EPS of $5.44, above the $5.25 consensus, representing 6% year-over-year growth. Revenue reached $11.01 billion, up 6% YoY (vs. $10.36 billion a year earlier), and also beat expectations of $10.87 billion.
- On a reported (GAAP) basis, EPS came in at $4.43 (+11% YoY), while operating income reached $1.86 billion (+9% YoY). Adjusted operating income totaled $2.40 billion (+6% YoY), with an operating margin of 21.8%, essentially unchanged from 21.9% a year ago.
Key issue: weak organic growth
The most important takeaway from the report is the structure of growth. Organic revenue growth was just 1%, indicating that most of the expansion was driven by acquisitions and external factors. In practice, this points to a slowdown in the core business, which helps explain the muted market reaction despite the earnings beat.
Acquisitions and capital allocation
In the first quarter, the company:
- acquired Clario (clinical trial data solutions),
- repurchased $3.0 billion worth of shares,
- increased its dividend by 10%.
This confirms the continuation of a growth strategy driven by M&A alongside active capital management.
New products and technological development
During the quarter, Thermo Fisher launched several new products, including:
- Glacios 3 Cryo-TEM microscope,
- TSQ Certis mass spectrometer,
- Niton XL5e analyzer,
- Gibco CTS Compleo system for cell therapy manufacturing.
These products target higher-value segments, particularly in life sciences and advanced laboratory research.
Strategic partnerships
The company also announced collaborations with:
- NVIDIA – integrating AI into laboratory instrumentation,
- SHL Medical – expanding pharmaceutical manufacturing and device capabilities.
These moves point toward further development in automation and the digitalization of research processes. Thermo Fisher delivered a solid set of results:
- Revenue growth: +6% YoY
- Adjusted EPS above consensus
- Stable operating margin (21.8%)
However, organic growth of just 1% remains the key constraint on the growth narrative. The market is clearly signaling that in the current environment, simply beating estimates is not enough — the pace and quality of underlying business growth matter more.
TMO (D1 interval)
Source: xStation5
Nvidia dominates Big Tech again 🗽 What does the U.S. earnings season show?
Tesla surges 4% after earnings supporting sentiments Wall Street 📈
US OPEN: Wall Street Shrugs Off Iran Concerns, Eyes Tesla Results
$2.8 billion at stake: Microsoft vs. UK regulators
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
